Glenmark Pharmaceuticals is currently trading at Rs 528.00, up by 5.75 points or 1.10% from its previous closing of Rs 522.25 on the BSE.
The scrip opened at Rs 524.45 and has touched a high and low of Rs 530.95 and Rs 520.40 respectively. So far 24352 shares were traded on the counter.
The BSE group 'A' stock of face value Re 1 has touched a 52 week high of Rs 612.00 on 12-Jul-2013 and a 52 week low of Rs 458.00 on 28-Mar-2013.
Last one week high and low of the scrip stood at Rs 532.70 and Rs 518.00 respectively. The current market cap of the company is Rs 14238.13 crore.
The promoters holding in the company stood at 48.31% while Institutions and Non-Institutions held 40.86% and 10.83% respectively.
Merrill Lynch Capital Markets Espana SA SV has reportedly bought 21.40 lakh shares or 0.79% stake of Glenmark Pharmaceuticals through the open market route. The shares were purchased on an average price of Rs 518.80 valuing the transaction to Rs 111.52 crore.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
The scrip opened at Rs 524.45 and has touched a high and low of Rs 530.95 and Rs 520.40 respectively. So far 24352 shares were traded on the counter.
The BSE group 'A' stock of face value Re 1 has touched a 52 week high of Rs 612.00 on 12-Jul-2013 and a 52 week low of Rs 458.00 on 28-Mar-2013.
Last one week high and low of the scrip stood at Rs 532.70 and Rs 518.00 respectively. The current market cap of the company is Rs 14238.13 crore.
The promoters holding in the company stood at 48.31% while Institutions and Non-Institutions held 40.86% and 10.83% respectively.
Merrill Lynch Capital Markets Espana SA SV has reportedly bought 21.40 lakh shares or 0.79% stake of Glenmark Pharmaceuticals through the open market route. The shares were purchased on an average price of Rs 518.80 valuing the transaction to Rs 111.52 crore.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
No comments:
Post a Comment